Hiroyuki Fujita

Yokohama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 145 publications

Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia.

Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia.

Journal: International journal of hematology

Published: September 03, 2025

Outcome of initial cord blood transplantation with FM80TBI as conditioning regimen for acute myeloid leukemia.

Outcome of initial cord blood transplantation with FM80TBI as conditioning regimen for acute myeloid leukemia.

Journal: Annals of hematology

Published: July 05, 2025

Delayed Methotrexate Elimination Following High-dose Methotrexate Prophylaxis in High-risk Diffuse Large B-cell Lymphoma.

Delayed Methotrexate Elimination Following High-dose Methotrexate Prophylaxis in High-risk Diffuse Large B-cell Lymphoma.

Journal: Internal medicine (Tokyo, Japan)

Published: March 16, 2025

Clinical utility and characteristics of comprehensive genomic profiling tests in patients with gynecologic cancer: a multi-institutional survey in Kinki District, Japan.

Clinical utility and characteristics of comprehensive genomic profiling tests in patients with gynecologic cancer: a multi-institutional survey in Kinki District, Japan.

Journal: International journal of clinical oncology

Published: February 25, 2025

The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Journal: Cardio-oncology (London, England)

Published: February 13, 2025

Correction: JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).

Correction: JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).

Journal: International journal of hematology

Published: December 24, 2024

Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: insights from a multicenter retrospective study in real-world practice.

Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: insights from a multicenter retrospective study in real-world practice.

Journal: Leukemia research

Published: November 30, 2024

A Case of Acquired Factor V Inhibitor During Bullous Pemphigoid Treatment.

A Case of Acquired Factor V Inhibitor During Bullous Pemphigoid Treatment.

Journal: Cureus

Published: September 10, 2024

JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).

JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).

Journal: International journal of hematology

Published: February 19, 2024

Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.

Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.

Journal: International journal of hematology

Published: October 19, 2023

Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).

Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).

Journal: International journal of hematology

Published: August 26, 2023

Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse.

Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse.

Journal: International journal of hematology

Published: July 10, 2023

Showing 1-12 of 145

Last Updated: 09/26/2026